ODAC To Evaluate Strength Of Objective Response Rate Of Arzerra In CLL

Meeting at the ASCO annual meeting, FDA’s oncology panel will consider whether the effect sizes of surrogate endpoints observed in patients refractory to two drugs justify accelerated approval of GSK/Genmab’s ofatumumab.